Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, View ORCID ProfileJudith Absalon, Alejandra Gurtman, Stephen Lockhart, View ORCID ProfileKathleen Neuzil, View ORCID ProfileVanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Ӧzlem Türeci, Kristin R. Tompkins, Edward E. Walsh, View ORCID ProfileRobert Frenck, View ORCID ProfileAnn R. Falsey, View ORCID ProfilePhilip R. Dormitzer, William C. Gruber, Uğur Şahin, Kathrin U. Jansen
doi: https://doi.org/10.1101/2020.06.30.20142570
Mark J. Mulligan
1New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirsten E. Lyke
2University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Kitchin
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Absalon
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Judith Absalon
  • For correspondence: judith.absalon@pfizer.com
Alejandra Gurtman
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Lockhart
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen Neuzil
2University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kathleen Neuzil
Vanessa Raabe
1New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vanessa Raabe
Ruth Bailey
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kena A. Swanson
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ping Li
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Koury
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Warren Kalina
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cooper
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camila Fontes-Garfias
6University of Texas Medical Branch, Galveston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pei-Yong Shi
6University of Texas Medical Branch, Galveston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ӧzlem Türeci
7BioNTech, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristin R. Tompkins
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward E. Walsh
4University of Rochester and Rochester General Hospital, Rochester, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Frenck
5Cincinnati Children’s Hospital, Cincinnati, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Frenck
Ann R. Falsey
4University of Rochester and Rochester General Hospital, Rochester, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ann R. Falsey
Philip R. Dormitzer
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip R. Dormitzer
William C. Gruber
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uğur Şahin
7BioNTech, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin U. Jansen
3Vaccine Research and Development, Pfizer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.

Competing Interest Statement

Competing interests NK, JA, AG, SL, RB, KS, PL, KK, WK, DC, KT, PRD, WG, and KUJ are employees of Pfizer and may hold stock options. US and ÖT are stock owners, management board members, and employees at BioNTech SE (Mainz, Germany) and are inventors on patents and patent applications related to RNA technology. MJM, KL, KN, EW, AF, RF, and VR received compensation from Pfizer for their role as study investigators. CFG and PYS received compensation from Pfizer to perform the neutralization assay.

Clinical Trial

ClinicalTrials.gov identifier: NCT04368728

Funding Statement

Role of the funding source: BioNTech is the Sponsor of the study. Pfizer was responsible for the design, data collection, data analysis, data interpretation, and writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit the data for publication. All study data were available to all authors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The final protocol and informed consent document were approved by institutional review boards for each of the participating investigational centers This study was conducted in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines and the ethical principles of the Declaration of Helsinki. A signed and dated informed consent form was required before any study-specific activity was performed.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵a Hurley, UK

  • ↵b Pearl River, NY

  • ↵c Collegeville, P.A

Data Availability

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual anonymized participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 01, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Ӧzlem Türeci, Kristin R. Tompkins, Edward E. Walsh, Robert Frenck, Ann R. Falsey, Philip R. Dormitzer, William C. Gruber, Uğur Şahin, Kathrin U. Jansen
medRxiv 2020.06.30.20142570; doi: https://doi.org/10.1101/2020.06.30.20142570
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Vanessa Raabe, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Ӧzlem Türeci, Kristin R. Tompkins, Edward E. Walsh, Robert Frenck, Ann R. Falsey, Philip R. Dormitzer, William C. Gruber, Uğur Şahin, Kathrin U. Jansen
medRxiv 2020.06.30.20142570; doi: https://doi.org/10.1101/2020.06.30.20142570

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (450)
  • Dentistry and Oral Medicine (82)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5248)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (755)
  • Geriatric Medicine (80)
  • Health Economics (212)
  • Health Informatics (696)
  • Health Policy (356)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5849)
  • Intensive Care and Critical Care Medicine (358)
  • Medical Education (103)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (762)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (476)
  • Ophthalmology (150)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (140)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (860)
  • Public and Global Health (2004)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (283)
  • Rheumatology (94)
  • Sexual and Reproductive Health (73)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)